Panitumumab + Olaparib + Dabrafenib + Nilotinib + Trametinib + Erlotinib + Trastuzumab and Pertuzumab (combination treatment) + Vemurafenib and Cobimetinib (combination treatment) + Vismodegib + Regorafenib + Nivolumab + Afatinib + Dabrafenib and trametinib + Ribociclib + Lenvatinib + Pembrolizumab + Durvalumab + Rucaparib + Axitinib + Palbociclib + Crizotinib + Sunitinib + Cabozantinib + Abemaciclib + Alectinib + Atezolizumab and Bevacizumab + Ipilimumab and nivolumab + Entrectinib + Talazoparib + Dacomitinib + Lorlatinib + Erdafitinib + Alpelisib + Niraparib + Pemigatinib + Selpercatinib + Tepotinib
Phase 2RecruitingDevelopment Stage
Cancer
Cancer, Tumors, Neoplasm, Neoplasia
Aug 1, 2016 → Dec 1, 2027
About Panitumumab + Olaparib + Dabrafenib + Nilotinib + Trametinib + Erlotinib + Trastuzumab and Pertuzumab (combination treatment) + Vemurafenib and Cobimetinib (combination treatment) + Vismodegib + Regorafenib + Nivolumab + Afatinib + Dabrafenib and trametinib + Ribociclib + Lenvatinib + Pembrolizumab + Durvalumab + Rucaparib + Axitinib + Palbociclib + Crizotinib + Sunitinib + Cabozantinib + Abemaciclib + Alectinib + Atezolizumab and Bevacizumab + Ipilimumab and nivolumab + Entrectinib + Talazoparib + Dacomitinib + Lorlatinib + Erdafitinib + Alpelisib + Niraparib + Pemigatinib + Selpercatinib + Tepotinib
Panitumumab + Olaparib + Dabrafenib + Nilotinib + Trametinib + Erlotinib + Trastuzumab and Pertuzumab (combination treatment) + Vemurafenib and Cobimetinib (combination treatment) + Vismodegib + Regorafenib + Nivolumab + Afatinib + Dabrafenib and trametinib + Ribociclib + Lenvatinib + Pembrolizumab + Durvalumab + Rucaparib + Axitinib + Palbociclib + Crizotinib + Sunitinib + Cabozantinib + Abemaciclib + Alectinib + Atezolizumab and Bevacizumab + Ipilimumab and nivolumab + Entrectinib + Talazoparib + Dacomitinib + Lorlatinib + Erdafitinib + Alpelisib + Niraparib + Pemigatinib + Selpercatinib + Tepotinib is a phase 2 stage product being developed by Eisai for Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02925234. Target conditions include Cancer, Tumors, Neoplasm.
What happened to similar drugs?
20 of 20 similar drugs in Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02925234 | Phase 2 | Recruiting |
Competing Products
20 competing products in Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mFOLFOX regimen + Mitazalimab | Alligator Bioscience AB | Phase 2/3 | 35 |
| Intratumoral Mitazalimab + Intratumoral Nivolumab | Alligator Bioscience AB | Phase 1 | 26 |
| mRNA-2416 | Moderna | Phase 2 | 0 |
| Doxorubicin Hydrochloride Liposome Injection | Dr. Reddy's Laboratories | Phase 1 | 26 |
| E7389 | Eisai | Phase 1 | 29 |
| Veliparib | AbbVie | Phase 2 | 27 |
| AK-105 | Akeso | Phase 1 | 29 |
| XL820 | Exelixis | Phase 1 | 26 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 30 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 30 |
| ALT-P7 (HM2-MMAE) | Alteogen | Phase 1 | 29 |
| pegylated liposomal doxorubicin (PLD) + PD-1 | CSPC Pharmaceutical Group Limited | Phase 2 | 31 |
| Biomarkers blood, urine and microbiota samples | Eli Lilly | Pre-clinical | 30 |
| gemcitabine + paclitaxel + bevacizumab | Eli Lilly | Phase 2 | 35 |
| pemetrexed | Eli Lilly | Phase 2 | 27 |
| LY3300054 + Prexasertib | Eli Lilly | Phase 1 | 29 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 18 |
| Cetuximab + Oxaliplatin + Capecitabine | Eli Lilly | Phase 2 | 35 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 27 |
| Gemcitabine + Adriamycine + Paclitaxel | Eli Lilly | Phase 2 | 35 |